tiprankstipranks
Advertisement
Advertisement

AVBP Stock Latest News

ArriVent BioPharma Stockholders Back Board and Auditor Slate
Company AnnouncementsArriVent BioPharma Stockholders Back Board and Auditor Slate
1d ago
8K
AVBP
ArriVent’s MRG007 Phase I Trial Progress Adds Long-Term Option Value for AVBP Investors
PremiumCompany Announcements
ArriVent’s MRG007 Phase I Trial Progress Adds Long-Term Option Value for AVBP Investors
20d ago
AVBP
Analyst Reiterates Buy on ArriVent, Maintains $42 Price Target on Firlotinib Confidence After Sunvozertinib Data
PremiumRatings
Analyst Reiterates Buy on ArriVent, Maintains $42 Price Target on Firlotinib Confidence After Sunvozertinib Data
23d ago
AVBP
ArriVent Biopharma assumed with a Buy at Truist
PremiumThe Fly
ArriVent Biopharma assumed with a Buy at Truist
26d ago
AVBP
ArriVent Biopharma price target lowered to $43 from $45 at Citi
PremiumThe Fly
ArriVent Biopharma price target lowered to $43 from $45 at Citi
1M ago
AVBP
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained
PremiumRatingsArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained
1M ago
AVBP
ArriVent BioPharma Updates At-The-Market Equity Offering Program
Premium
Company Announcements
ArriVent BioPharma Updates At-The-Market Equity Offering Program
1M ago
8K
AVBP
ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)
Premium
The Fly
ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)
1M ago
AVBP
ArriVent BioPharma, Inc. (AVBP) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
ArriVent BioPharma, Inc. (AVBP) Q1 Earnings Cheat Sheet
1M ago
AVBP
ArriVent Biopharma announces FDA clearance of ARR-002 NDA
PremiumThe Fly
ArriVent Biopharma announces FDA clearance of ARR-002 NDA
2M ago
AVBP
Buy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained
2M ago
AVBP
Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’
PremiumThe Fly
Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’
2M ago
AVBP
ArriVent Biopharma price target raised to $45 from $37 at B. Riley
PremiumThe FlyArriVent Biopharma price target raised to $45 from $37 at B. Riley
3M ago
AVBP
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
Premium
Company Announcements
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
3M ago
8K
AVBP
ArriVent Biopharma assumed with a Buy at BTIG
Premium
The Fly
ArriVent Biopharma assumed with a Buy at BTIG
3M ago
AVBP
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
PremiumRatings
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
3M ago
AVBP
ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer
PremiumThe Fly
ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer
4M ago
AVBP
ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright
PremiumThe Fly
ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright
4M ago
AVBP
ArriVent Biopharma price target raised to $33 from $31 at Citi
PremiumThe Fly
ArriVent Biopharma price target raised to $33 from $31 at Citi
4M ago
AVBP
Omega takes new stake in Rocket Companies, exits ArriVent Biopharma
PremiumThe FlyOmega takes new stake in Rocket Companies, exits ArriVent Biopharma
4M ago
ET
ABR
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential
Premium
Ratings
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential
5M ago
AVBP
ArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout
Premium
Ratings
ArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout
5M ago
AVBP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >